AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 221 min read$ROIV

Sukhatme Mayukh sold $12.4M of ROIV

Sukhatme Mayukh (President & CIO) sold 335,174 shares of Roivant Sciences Ltd. (ROIV) at an average of $36.88 ($36.48–$37.30, $12.36M total) across 3 trades over 2026-08-19 to 2026-08-21.

Original reporting
SEC EDGAR · Sukhatme Mayukh
Published Aug 22, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Bearish
medium confidence
Mentioned
$ROIV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVBearishLow
01

Why it matters

The sale reduces insider ownership to 18.6M shares, indicating a 1.8% stake after the transaction.

02

Market read

First public disclosure of a significant insider sale; may influence short-term trading sentiment.

03

What to watch

Potential upcoming financing or strategic moves not disclosed.

Relevance 7/10Novelty 7/10Timing: filed 2026-08-21

Background

SEC Form 4 filing discloses insider transaction for Roivant Sciences Ltd.

Company-level read

Ticker impact

$ROIVBearishMedium confidence
Context

Form 4 shows President & CIO sold 335,174 shares for $12.36M, reducing his stake.

Expected impact

Possible modest price dip in near term.

Evidence & confidence

Insider sale of $12M by a top executive is material but not unusual; market may react cautiously.

Market effects

Sector

Minimal impact on biotech sector; insider activity is company-specific.

Regional

Limited to US-listed biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company outlook.

Key entities

  • Officer
    Sukhatme Mayukh

    President & CIO of Roivant Sciences Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

OCT 5
$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.

benzinga.com3 min
OCT 5
Med

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.

biospace.com3 min
SEP 24
$ROIVMedAI 8/10

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.

insidermonkey.com3 min